Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-1299-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Myeloperoxidase (MPO) Monoclonal Antibody (MPO455-8E6), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The monoclonal antibody MPO455-8E6 recognizes myeloperoxidase (MPO), a protein within the azurophilic granules of myeloid cells. MPO is a multimeric protein comprised of two 55 kDa subunits and two 15 kDa subunits. The larger subunits associate with a heme protein resulting in a greenish color. As an enzyme, MPO breaks down hydrogen peroxide and oxidizes tyrosine. The products of this reaction, hypochlorous acid and tyrosyl radical, causethe cytotoxic and killing effects characteristic of neutrophils. Myeloperoxidase is important in the diagnosis of some cancers and increases in serum levels have been shown to correlate with cardiac events. Applications Reported: This MPO455-8E6 antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This MPO455-8E6 antibody has been pre-titrated and tested by intracellular staining followed by flow cytometric analysis of normal human peripheral blood cells using the Intracellular Fixation & Permeablization Buffer Set (Product # 88-8824-00). For best results, whole blood should first be stained with antibodies to surface antigens then treated with 1X RBC lysis buffer (Product # 00-4333-57) to lyse erythrocytes. Then, for intracellular staining for MPO, cells should be fixed with IC Fixation Buffer (Product # 00-8222-49) washed two times with Permeabilization Buffer (Product # 00-8333-56) and then incubated with MPO455-8E6 for 30-60 minutes. After washing, cells may be analyzed on a flow cytometer. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Antibody clone number
- MPO455-8E6
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Generation of Human Neutrophils from Induced Pluripotent Stem Cells in Chemically Defined Conditions Using ETV2 Modified mRNA.
Loss of testosterone impairs anti-tumor neutrophil function.
Innate Response Activator (IRA) B Cells Reside in Human Tonsils and Internalize Bacteria In Vitro.
Majumder A, Suknuntha K, Bennin D, Klemm L, Brok-Volchanskaya VS, Huttenlocher A, Slukvin I
STAR protocols 2020 Sep 18;1(2)
STAR protocols 2020 Sep 18;1(2)
Loss of testosterone impairs anti-tumor neutrophil function.
Markman JL, Porritt RA, Wakita D, Lane ME, Martinon D, Noval Rivas M, Luu M, Posadas EM, Crother TR, Arditi M
Nature communications 2020 Mar 31;11(1):1613
Nature communications 2020 Mar 31;11(1):1613
Innate Response Activator (IRA) B Cells Reside in Human Tonsils and Internalize Bacteria In Vitro.
Chiappini N, Cantisani R, Pancotto L, Ruggiero P, Rosa D, Manetti A, Romano A, Montagnani F, Bertholet S, Castellino F, Del Giudice G
PloS one 2015;10(6):e0129879
PloS one 2015;10(6):e0129879
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Intracellular staining of normal human peripheral blood cells with Mouse IgG1 K Isotype Control PE (Product # 12-4714-81) (left) or Anti-Human Myeloperoxidase (MPO) PE (right) using the Intracellular Fixation & Permeabilization Buffer Set (Product # 88-8824-00). Total viable cells were used for analysis.
- Conjugate
- Yellow dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 5 Analysis of neutrophils from control or androgen deprivation therapy (ADT) treated patients. a Percent of circulating neutrophils from control or ADT treated prostate cancer patients that have a mature, segmented appearance morphologically. b Percent Cd11b + CD66b + CD16 lo neutrophils. c Percent myeloid derived suppressor cell (MDSC)-like neutrophils defined as HLA-DR - CD14 - CD33 + CD15 + . d Percent fold change in migration (percent crystal violet positive area of transwell stimulated with a chemoattractant divided by percent area without chemoattractant). e Percent of unstimulated neutrophils producing DHR123. f Percent of neutrophils producing DHR123 following PMA stimulation. g Percent myeloperoxidase + (MPO + ) neutrophils. h Percent of plated netosising neutrophils at 1 and 3 h following purification. Data in a - h are mean +- s.e.m., * p < 0.05, ** p < 0.01, *** p < 0.001 by multivariable linear regression using ADT as its main predictor and adjusting for presence of prostatectomy, age, race, and current status; control prostate cancer patients ( n = 8 in a , c , g and n = 7 in b , d , e , f , h ) and prostate cancer pati e nts receiving ADT ( n = 22 in a , c , g and n = 21 in b , d , e , f , h ).
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 Induction of Neutrophil Formation from Myeloid Progenitors (A) Representative images of Wright stained cytospins showing the morphology of neutrophils. (B) Flow cytometric analysis of CD11b, CD15, CD16, CD66b, MPO and lactoferrin expression in generated neutrophils.
- Conjugate
- Yellow dye